GLP-1 & Metabolic Peptides

Metabolic research is currently dominated by incretin receptor peptides. Semaglutide is the GLP-1 reference compound, Tirzepatide adds the GIP receptor, and Retatrutide addresses GLP-1, GIP and glucagon receptors at once. All three are supplied as lyophilised powder in sealed vials, from 2 mg to 30 mg depending on the compound.

Retatrutide and Tirzepatide carry a certificate of analysis on file for documented batches.